DIAMOND-1 Phase 3 trial, assessing efficacy and safety of OCS-01 eye drops in Diabetic Macular Edema (DME) patients, was initiated as planned. Second Phase 3 trial, DIAMOND-2, anticipated to start in Q1 2024 Stage 1 results showed superiority of OCS-01 eye drops vs. vehicle with robust statistical significance with no unexpected adverse events observed If approved, OCS-01 has the potential to be